Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Corporate Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases August 2, 2022 Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 18, 2022 Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo July 12, 2022 Incyte to Report Second Quarter Financial Results All press releases Latest Events Aug 2 2022 Aug 2 2022 Q2 2022 Incyte Corporation Earnings Conference Call Click here for Webcast Supporting Materials Q2 2022 Financial and Corporate Update Presentation 3 MB Jul 19 2022 Jul 19 2022 FDA Approval Call for Opzelura in Vitiligo Click here for Webcast Supporting Materials Presentation 4.8 MB Patient video All events
